Advertisement

Gerinnungsabklärung und Therapie bei habituellen Aborten und wiederholtem Implantationsversagen

  • Nina Rogenhofer
  • Michael K. BohlmannEmail author
Leitthema
  • 6 Downloads

Zusammenfassung

Rezidivierende habituelle Spontanaborte betreffen etwa 1–3 % aller Partnerschaften. Neben genetischen, endokrinen, anatomischen, autoimmunen und infektiösen Ursachen wurden in der Vergangenheit auch thrombophile Faktoren im Kontext der Pathogenese dieses Krankheitsbilds diskutiert. In Analogie hierzu wird unter dem Begriff des rezidivierenden Implantationsversagens die Konstellation verstanden, dass es im Rahmen einer Behandlung mit In-vitro-Fertilisation bzw. intrazytoplasmatischer Spermieninjektion nach mehreren Embryonentransfers zu keinem Schwangerschaftseintritt gekommen ist. Auch für diese Konstellation wurden mütterliche Thrombophilien verantwortlich gemacht. Die vorliegende Übersichtsarbeit stellt die aktuelle Datenlage zur Diagnostik und Therapie beider Entitäten dar.

Schlüsselwörter

Gerinnungsstörungen Antikoagulanzien Heparin Acetylsalicylsäure Thrombophilie 

Coagulation diagnostics and treatment for recurrent pregnancy loss and implantation failure

Abstract

Recurrent spontaneous abortions (RSA) affect 1%–3% of all couples. In addition to genetic, endocrine, anatomical, autoimmune and infectious causes, maternal thrombophilia has been discussed as a risk factor for this disease. Like RSA, recurrent implantation failure (RIF) is understood as a constellation in which no pregnancy occurs after several embryo transfers in the course of multiple in vitro fertilization and intracytoplasmic sperm injection (IVF/ICSI) cycles. RIF has also been attributed to maternal thrombophilia. This review article summarizes the current data on diagnosis and treatment of both diseases with regard to maternal thrombophilia.

Keywords

Coagulation disorders Anticoagulants Heparin Aspirin Thrombophilia 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

N. Rogenhofer und M.K. Bohlmann geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Literatur

  1. 1.
    ESHRE Early Pregnancy Guideline Development Group (2017) Recurrent pregnancy lossGoogle Scholar
  2. 2.
    Royal College of Obstetricians and Gynaecologists (2011) The investigation and treatment of couples with recurrent first-trimester ans second-trimester miscarriage. Green-top guideline No. 17Google Scholar
  3. 3.
    American College of Obestetricians and Gynecologists (2002) ACOG practice bulletin. Management of recurrent pregnancy loss. Number 24, February 2001. (Replaces Technical Bulletin Number 212, September 1995). American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 78:179–190CrossRefGoogle Scholar
  4. 4.
    Toth B, Jeschke U, Rogenhofer N, Scholz C, Wurfel W, Thaler CJ, Makrigiannakis A (2010) Recurrent miscarriage: Current concepts in diagnosis and treatment. J Reprod Immunol 85:25–32CrossRefGoogle Scholar
  5. 5.
    Roberts LN, Patel RK, Arya R (2009) Venous thromboembolism and ethnicity. Br J Haematol 146:369–383CrossRefGoogle Scholar
  6. 6.
    Bates SM et al (2012) VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(Suppl 2):e691S–e736SCrossRefGoogle Scholar
  7. 7.
    Markoff A, Bogdanova N, Samama MM (2011) Hereditary thrombophilic risk factors for recurrent pregnancy loss. Hereditary Genet 1:103Google Scholar
  8. 8.
    Buchholz T, Lohse P, Rogenhofer N, Kosian E, Pihusch R, Thaler CJ (2003) Polymorphisms in the ACE and PAI-1 genes are associated with recurrent spontaneous miscarriages. Hum Reprod 18:2473–2477CrossRefGoogle Scholar
  9. 9.
    College of American Pathologists Consensus Conference XXXVI (2002) Diagnostic Issues in Thrombophilia. Arch Pathol Lab Med 126(11):1277–433Google Scholar
  10. 10.
    Rey E et al (2003) Thrombophilic disorders and fetal loss: A meta-analysis. Lancet 361:901–908CrossRefGoogle Scholar
  11. 11.
    Rodger MA, Betancourt MT, Clark P, Lindqvist PG, Dizon-Townson D, Said J, Seligsohn U, Carrier M, Salomon O, Greer IA (2010) The association of factor V leiden and prothrombin gene mutation and placenta-mediated pregnancy complications: A systematic review and meta-analysis of prospective cohort studies. PLoS Med 7:e1000292CrossRefGoogle Scholar
  12. 12.
    Silver RM et al (2010) Prothrombin gene G20210A mutation and obstetric complications. Obstet Gynecol 115:14–20CrossRefGoogle Scholar
  13. 13.
    Pihusch R, Buchholz T, Lohse P, Rübsamen H, Rogenhofer N, Hasbargen U, Hiller E, Thaler CJ (2001) Thrombophilic gene mutations and recurrent spontaneous abortion: Prothrombin mutation increases the risk in the first trimester. Am J Reprod Immunol 46:124–131CrossRefGoogle Scholar
  14. 14.
    Bouter A, Gounou C, Bérat R, Tan S, Gallois B, Granier T, d’Estaintot BL, Pöschl E, Brachvogel B, Brisson AR (2011) Annexin-A5 assembled into two-dimensional arrays promotes cell membrane repair. Nat Commun 2:270CrossRefGoogle Scholar
  15. 15.
    Chinni E, Tiscia GL, Colaizzo D, Vergura P, Margaglione M, Grandone E (2010) Annexin V expression in human placenta is influenced by the carriage of the common haplotype M2. Fertil Steril 91:940–942CrossRefGoogle Scholar
  16. 16.
    Shu F, Sugimura M, Kanayama N, Kobayashi H, Kobayashi T, Terao T (2000) Immunohistochemical study of annexin V expression in placentae of preeclampsia. Gynecol Obstet Invest 49:17–23CrossRefGoogle Scholar
  17. 17.
    Sifakis S, Soufla G, Koukoura O et al (2010) Decreased annexin A5 mRNA placental expression in pregnancies complicated by fetal growth restriction. Thromb Res 125:326–331CrossRefGoogle Scholar
  18. 18.
    Bogdanova N, Horst J, Chlystun M, Croucher PJ, Nebel A, Bohring A, Todorova A, Schreiber S, Gerke V, Krawczak M, Markoff A (2007) A common haplotype of the annexin A5 (ANXA5) gene promoter is associated with recurrent pregnancy loss. Hum Mol Genet 16:573–578CrossRefGoogle Scholar
  19. 19.
    Rogenhofer N, Engels L, Bogdanova N, Tüttelmann F, Markoff A, Thaler C (2012) Paternal and maternal carriage of the annexin A5 M2 haplotype are equal risk factors for recurrent pregnancy loss: A pilot study. Fertil Steril 98:383–388CrossRefGoogle Scholar
  20. 20.
    Baumann K, Beuter-Winkler P, Hackethal A, Strowitzki T, Toth B, Bohlmann MK (2013) Maternal factor V Leiden and prothrombin mutations do not seem to contribute to the occurrence of two or more than two consecutive miscarriages in Caucasian patients. Am J Reprod Immunol 70:518–521CrossRefGoogle Scholar
  21. 21.
    Practice Committee of the American Society for Reproductive Medicine (2008) Definitions of infertility and recurrent pregnancy loss. Fertil Steril 89:1603CrossRefGoogle Scholar
  22. 22.
    Toth B, Würfel W, Bohlmann M, Zschocke J, Rudnik-Schöneborn S, Nawroth F, Schleußner E, Rogenhofer N, Wischmann T, von Wolff M, Hancke K, von Otte S, Kuon R, Feil K, Tempfer C (2018) Recurrent miscarriage: Diagnostic and therapeutic procedures. Guideline of the DGGG, OEGGG and SGGG (S2k-level, AWMF registry number 015/050). Geburtshilfe Frauenheilkd 78:364–381CrossRefGoogle Scholar
  23. 23.
    Sarig G et al (2005) Modulation of systemic hemostatic parameters by enoxaparin during gestation in women with thrombophilia and pregnancy loss. Thromb Haemost 94:980–985CrossRefGoogle Scholar
  24. 24.
    Clark P et al (2010) SPIN (Scottish Pregnancy Intervention) study: A multicenter, randomized controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage. Blood 115:4162–4167CrossRefGoogle Scholar
  25. 25.
    Kaandorp SP et al (2010) Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med 362:1586–1596CrossRefGoogle Scholar
  26. 26.
    Rogenhofer N, Schleussner E, Kamin G, Seeliger G, Toth B (2013) No benefit of low molecular weight heparin in recurrent pregnancy loss—Results of the ETHIG II study. Hum Reprod 28(Suppl 1):i4–i6CrossRefGoogle Scholar
  27. 27.
    Schleussner E, Kamin G, Seliger G, Rogenhofer N, Ebner S, Toth B, Schenk M, Henes M, Bohlmann MK, Fischer T, Brosteanu O, Bauersachs R, Petroff D (2015) Low-molecular-weight heparin for women with unexplained recurrent pregnancy loss: A multicenter trial with a minimization randomization scheme. Ann Intern Med 162:601–609CrossRefGoogle Scholar
  28. 28.
    Tan WK et al (2012) Does low-molecular-weight heparin improve live birth rates in pregnant women with thrombophilic disorders? A systematic review. Singapore Med J 53:659–663PubMedGoogle Scholar
  29. 29.
    Visser J et al (2011) Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia. HABENOX: A randomised multicentre trial. Thromb Haemost 105:295–301CrossRefGoogle Scholar
  30. 30.
    Mantha S, Bauer KA, Zwicker JI (2010) Low molecular weight heparin to achieve live birth following unexplained pregnancy loss: a systematic review. J Thromb Haemost 8(2):263–8CrossRefGoogle Scholar
  31. 31.
    Bohlmann MK (2011) Effects and effectiveness of heparin in assisted reproduction. J Reprod Immunol 90:82–90CrossRefGoogle Scholar
  32. 32.
    American College of Obstetricians and Gynecologists (2013) ACOG Practice Bulletin No. 138: Inherited thrombophilias in pregnancy. Obstet Gynecol 122:706–717CrossRefGoogle Scholar
  33. 33.
    Rogenhofer N, Bohlmann MK, Beuter-Winkler P, Würfel W, Rank A, Thaler CJ, Toth B (2014) Prevention, management and extent of adverse pregnancy outcomes in women with hereditary antithrombin deficiency. Ann Hematol 93:385–392CrossRefGoogle Scholar
  34. 34.
    Bauersachs RM et al (2007) Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women. Thromb Haemost 98:1237–1245CrossRefGoogle Scholar
  35. 35.
    Gris JC (2011) LMWH have no place in recurrent pregnancy loss: Debate – Against the motion. Thromb Res 127(Suppl 3):S110–S112CrossRefGoogle Scholar
  36. 36.
    de Jong PG, Kaandorp S, Di Nisio M, Goddijn M, Middeldorp S (2014) Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. Cochrane Database Syst Rev 7:CD4734Google Scholar
  37. 37.
    Check JH (2012) The use of heparin for preventing miscarriage. Am J Reprod Immunol 67:326–333CrossRefGoogle Scholar
  38. 38.
    Bashiri A, Halper KI, Orvieto R (2018) Recurrent implantation failure-update overview on etiology, diagnosis, treatment and future directions. Reprod Biol Endocrinol 16:121CrossRefGoogle Scholar
  39. 39.
    Zeyneloglu HB, Onalan G (2014) Remedies for recurrent implantation failure. Semin Reprod Med 32:297–305CrossRefGoogle Scholar
  40. 40.
    Nelson SM, Greer IA (2008) The potential role of heparin in assisted conception. Hum Reprod Update 14:623–645CrossRefGoogle Scholar
  41. 41.
    Sharif KW, Ghunaim S (2010) Management of 273 cases of recurrent implantation failure: Results of a combined evidence-based protocol. Reprod Biomed Online 21:373–380CrossRefGoogle Scholar
  42. 42.
    Coulam CB, Jeyendran RS, Fishel LA, Roussev R (2006) Multiple thrombophilic gene mutations are risk factors for implantation failure. Reprod Biomed Online 12:322–327CrossRefGoogle Scholar
  43. 43.
    Ata B, Urman B (2016) Thrombophilia and assisted reproduction technology-any detrimental impact or unnecessary overuse? J Assist Reprod Genet 33:1305–1310CrossRefGoogle Scholar
  44. 44.
    Lodigiani C, di Micco P, Ferrazzi P, Libre L, Arfuso V, Polatti F, Benigna M, Rossini R, Morenghi E, Rota L, Brenner B, Setti PE (2011) Low-molecular-weight heparin in women with repeated implantation failure. Womens Health 7:425–431Google Scholar
  45. 45.
    Potdar N, Gelbaya TA, Konje JC, Nardo LG (2013) Adjunct low-molecular-weight heparin to improve live birth rate after recurrent implantation failure: A systematic review and meta-analysis. Hum Reprod Update 19:674–684CrossRefGoogle Scholar
  46. 46.
    Qublan H, Amarin Z, Dabbas M, Farraj AE, Beni-Merei Z, Al-Akash H, Bdoor AN, Nawasreh M, Malkawi S, Diab F et al (2008) Low-molecular-weight heparin in the treatment of recurrent IVF-ET failure and thrombophilia: A prospective randomized placebo-controlled trial. Hum Fertil 11:246–253CrossRefGoogle Scholar
  47. 47.
    Berker B, Taskin S, Kahraman K, Taskin EA, Atabekoglu C, Sonmezer M (2011) The role of low-molecular-weight heparin in recurrent implantation failure: A prospective, quasi-randomized, controlled study. Fertil Steril 95:2499–2502CrossRefGoogle Scholar
  48. 48.
    Urman B, Ata B, Yakin K, Alatas C, Aksoy S, Mercan R, Balaban B (2009) Luteal phase empirical low molecular weight heparin administration in patients with failed ICSI embryo transfer cycles: A randomized open-labeled pilot trial. Hum Reprod 24:1640–1647CrossRefGoogle Scholar
  49. 49.
    Nardo LG, El-Toukhy T, Stewart J, Balen AH, Potdar N (2015) British Fertility Society Policy and Practice Committee: Adjuvants in IVF: Evidence for good clinical practice. Hum Fertil (Camb) 18:2–15CrossRefGoogle Scholar
  50. 50.
    Simcox LE, Ormesher L, Tower C, Greer IA (2015) Thrombophilia and pregnancy complications. Int J Mol Sci 16:28418–28428CrossRefGoogle Scholar
  51. 51.
    Siristatidis C, Dafopoulos K, El-Khayat W, Salamalekis G, Anifandis G, Vrantza T, Elsadek M, Papantoniou N (2018) Administration of prednisolone and low molecular weight heparin in patients with repeated implantation failures: A cohort study. Gynecol Endocrinol 34:136–139CrossRefGoogle Scholar
  52. 52.
    Hamdi K, Danaii S, Farzadi L, Abdollahi S, Chalabizadeh A, Abdollahi Sabet S (2015) The role of heparin in embryo implantation in women with recurrent implantation failure in the cycles of assisted reproductive techniques (without history of thrombophilia). J Family Reprod Health 9:59–64PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Klinik und Poliklinik für Frauenheilkunde und GeburtshilfeLMU MünchenMünchenDeutschland
  2. 2.FrauenklinikSt. Elisabethen-Krankenhaus LörrachLörrachDeutschland

Personalised recommendations